EXPLORE!

Sitagliptin serves as an add-on therapy for reducing the glycated hemoglobin level in a geriatric patient

  803 Views

eMediNexus    29 July 2022

A 91-year-old Japanese woman was diagnosed with acute onset of type 1 diabetes (T1D) two years back. 

 

Before three months, her HbA1c had been 9.5%. The patient was on premixed biphasic insulin aspart (30% insulin aspart and 70% protamine-complexed insulin aspart), thrice daily, which she took before her major meals. In addition, she was taking miglitol and aliskiren.

 

Her post-meal C-peptide levels were undetectable and the 24-hour urine C-peptide was below 1.1 mg/day. Her insulin antibodies were positive; the post-meal glucagon level was 130 pg/ml. Postprandial blood glucose was 252 mg/dl and HbA1c was 9.6% at presentation.

 

The lady was prescribed sitagliptin 25 mg/day. Within 20 weeks after sitagliptin therapy, miglitol could be discontinued. At the 24-week follow-up, her HbA1c plummeted to 7.4% despite no change in insulin doses.

 

Post-therapy, her post-meal C-peptide levels remained undetectable. There were no severe adverse events or signs of organ damage on evaluation during follow-ups. Further, the patient did not experience weight gain or gastrointestinal side effects.

 

Thus, sitagliptin therapy successfully modulated the glycated hemoglobin levels in this geriatric patient with T1D without any side effects.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.